



Attorney Docket: 147.50194  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: REGINA SCHOEMAKER

Serial No.: 09/917,858 Group Art Unit: 1615

Filed: JULY 31, 2001 Examiner: L. S. CHANNAVAJJALA

Title: USE OF MOXONIDINE FOR POSTMYOCARDIAL INFARCTION TREATMENT

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Mail Stop RCE  
Director of the USPTO  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is a Request for Continued Examination (RCE) under 37 CFR § 1.114 of the above-identified application.

1. Submission required under 37 CFR § 1.114

- a.  Previously submitted
  - i.  Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_
  - ii.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
  - iii.  Other \_\_\_\_\_

b. Enclosed

- i.  Amendment/Reply
- ii.  Affidavit(s)/Declaration(s)
- iii.  Information Disclosure Statement (IDS)
- iv.  Other

2. Miscellaneous

- a.  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months (not

2100448


12/15/2003 SDENB0B1 00000082 09917858

02 FC:1801 770.00 DA

to exceed three months). The required fee under 37 CFR 1.17(i) is included in Section 3. a. iii. below.

- b.  Other
3. Fees
- a.  The following fees are included in the payment indicated below:
- i.  RCE fee required under 37 CFR 1.17(e) (\$770)
  - ii.  Extension of time fee required under 37 CFR 1.136 & 1.17
  - iii.  Other \_
- b.  Payment:
- i.  A check in the amount of \$2,010 is enclosed
  - ii.  The Director is hereby authorized to charge the fees listed above in Section 3 a i-iii to the Deposit Account of Crowell & Moring, L.L.P., Account No. 05-1323 (Docket No. \*)
  - iii.  If a check should become detached or if there is any deficiency in fees, any necessary fees should be charged, or any overpayment in fees should be credited, to the Deposit Account of Crowell & Moring, L.L.P., Account No. 05-1323 (Docket No. 147/50194).

Respectfully submitted,

  
J. D. Evans  
Registration No. 26,269

Christopher T. McWhinney  
Registration No. 42,875

CROWELL & MORING, LLP  
P.O. Box 14300  
Washington, DC 20044-4300  
Telephone No.: (202) 624-2500  
Facsimile No.: (202) 628-8844

JDE/CTM/lw

2100448



RCE #  
Attorney Docket: 147.50194  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: REGINA SCHOEMAKER  
Serial No.: 09/917,858 Group Art Unit: 1615  
Filed: JULY 31, 2001 Examiner: L. S. CHANNAVAJJALA  
Title: USE OF MOXONIDINE FOR POSTMYOCARDIAL INFARCTION TREATMENT

REPLY

Mail Stop RCE  
Director of the USPTO  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The following remarks are respectfully submitted in response to the Office Action dated November 14, 2002 (the Office Action).

Remarks begin on page 2 of this paper.

